Iteos Home

Press Releases

Home / Investors / iTeos Therapeutics to Participate in Upcoming U.S. Conferences in March

Press Release Details

iTeos Therapeutics to Participate in Upcoming U.S. Conferences in March

March 6, 2019
PDF Version

Gosselies, Belgium – March 5, 2019 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present in two upcoming U.S. conferences in March. 

 

  • Cowen & Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 11:30 a.m. ET in Boston, MA.
  • William Blair 9th Annual Cancer Immunotherapy Conference on Thursday, March 21, 2019 at 3:15 p.m. ET in New York, NY.

 

About iTeos Therapeutics

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is a best in class adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.

 

For further information, please contact:

Michel Detheux, CEO
iTeos Therapeutics
info@iteostherapeutics.com 

 

Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com

 

Sarah McCabe and Carl Mauch
Stern Investor Relations, Inc.
+ 1 212 362 1200
iTeos@sternir.com 

For investors

scientist picking up a petri dish

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.